Myths vs. Facts: Getting Synagis (Palivizumab) Covered by Aetna (CVS Health) in New Jersey
Answer Box: Fast Track to Synagis Approval in New Jersey
Synagis (palivizumab) requires prior authorization from Aetna (CVS Health) with step therapy mandating Beyfortus (nirsevimab) first-line unless contraindicated. High-risk infants (<29 weeks gestation, chronic lung disease, or hemodynamically significant congenital heart disease) need specialist documentation and proof Beyfortus is